- The US30 is extending its gains after reaching a record closing level yesterday.
- The index is supported by a capital rotation from the technology sector into traditional value stocks.
- Among yesterday’s top performers on Wall Street were biotech stocks, which continue their strong momentum in premarket trading.
- The US30 is extending its gains after reaching a record closing level yesterday.
- The index is supported by a capital rotation from the technology sector into traditional value stocks.
- Among yesterday’s top performers on Wall Street were biotech stocks, which continue their strong momentum in premarket trading.
The US30 continues its upward momentum after closing yesterday’s session at a record high of around 48,000 (+1.3%), driven by a massive rotation of capital across Wall Street. While the potential end of the U.S. government shutdown supports broad market optimism, persistent concerns over high valuations in the AI sector have redirected capital toward more traditional value stocks.
The US30 successfully broke above the 30-day exponential moving average, consolidating its position by closing above the previously established resistance near 47,860. Holding above the psychological level of 48,000 will be key for further gains toward the upper boundary of the recent technical structure, though the RSI entering overbought territory may limit optimism for the index’s value-oriented names. (Source: xStation5)
What’s driving the US30 today?
-
The U.S. House of Representatives (the lower chamber of Congress) will vote today on the Senate’s federal funding bill, whose approval could pave the way to ending the more than 40-day government shutdown. The bill provides for full federal funding through January 2026, an annual budget for key agencies, and the payment of frozen wages to federal employees.
-
The Dow Jones Industrial Average, like other major U.S. indices, returned to gains early this week after the bill passed the Senate with the support of eight moderate Democrats. However, the broad market euphoria proved short-lived, as Tuesday saw a massive rotation of capital from growth stocks into more defensive sectors such as consumer staples and healthcare.
-
The technology sector remains weighed down by valuation concerns, as shown by Nvidia’s nearly 3% drop yesterday, deepened by SoftBank’s complete divestment of its Nvidia stake and disappointing results from AI cloud provider CoreWeave.
-
The new record high for the DJIA was primarily driven by biotech stocks, which led gains during yesterday’s session (Merck & Co.: +4.8%, Amgen: +4.6%, Johnson & Johnson: +2.9%). The only decliners in the index were Nvidia, JPMorgan, Caterpillar, and Cisco. Interestingly, the tech sell-off spared Apple (+1.7%), which, as a hardware and product-based company, straddles both growth and value characteristics.
Infineon after Earnings: Massive growth on massive promises
US government hopes boost risk, as bond market may not prop up Starmer
Heico shares near all-time high amid Axillon Fuel Containment acquisition 📈
DE40: DAX gains almost 1% 📈Bayern shares rise after earnings report
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
